Is Savient Pharmaceuticals, Inc. (NASDAQ:SVNT) ready to raly soon? Prominent investors are taking a bearish view. The number of bullish hedge fund bets retreated by 1 in recent months.

BRIDGEWATER, N.J., May 15, 2013 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today reported financial results for the three months ended March 31, 2013.

New York, NY - (NISMAGAZINE) - 05/15/2013- Savient Pharmaceuticals Inc (NASDAQ:SVNT) is trading down by 13.36% to $0.580, with total traded volumes of 1.78 million in comparison to its average volume of 0.228 million.

Shares of Savient Pharmaceuticals (NASDAQ: SVNT) opened at 0.57 on Friday. Savient Pharmaceuticals has a 52 week low of $0.48 and a 52 week high of $2.95.

Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) is a specialty biopharmaceutical company focused on developing KRYSTEXXA (pegloticase), or KRYSTEXXA, for the treatment of chronic gout in patients refractory to conventional therapy.

NEW YORK, May 16, 2013 - (Tech Sonian) - Pennystocksgainer web site will provide information on current or active penny stocks, as well as the most gainers of the day chart.

We provide treatment information, advice from physicians, nutritionists and dietitians, physical fitness experts, and health psychologists.

Affymax, Inc. (Nasdaq:AFFY); BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX); Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT); and Savient Pharmaceuticals Inc. (Nasdaq:SVNT). The NASDAQ Biotechnology Index is the basis for the iShares NASDAQ ...

On the flip side, Savient Pharmaceuticals Inc (NASDAQ:SVNT) fell -14.07% to $0.580 and ranged between $0.56 and $0.66 as its Q1 loss and revenue missed analysts' estimates.

Law360, New York (May 13, 2013, 7:39 PM ET) -- Savient Pharmaceuticals Inc. has hit CVS Caremark Corp. and Cardinal Health Inc. with a nearly $1.4 million breach of contract lawsuit in New Jersey over CVS' alleged attempts to return hundreds of opened ...